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Abstract
Background: Several common aspects of endothelial phenotype, such as the expression of cell
adhesion molecules, are shared between metastasis and inflammation. Here, we analyzed VCAM-
1 variants as biological markers of these two types of endothelial cell activation. With the
combination of 2-DE and western blot techniques and the aid of tunicamycin, we analyzed N-
glycosylation variants of VCAM-1 in primary human endothelial cells stimulated with either TNF or
tumoral soluble factors (TSF's) derived from the human breast cancer cell line ZR75.30.
Results: Treatments induced a pro-adhesive endothelial phenotype. 2D western blots analysis of
cells subjected to both treatments revealed the expression of the two known VCAM-1 isoforms
and of previously unknown isoforms. In particular TSFZR75.30 induced an isoform with a relative
molecular mass (Mr) and isoelectric point (pI) of 75-77 kDa and 5.0, respectively.
Conclusion: The unknown isoforms of VCAM-1 that were found to be overexpressed after
treatment with TSF's compared with TNF, could serve as biomarkers to discriminate between
inflammation and metastasis. 2D western blots revealed three new VCAM-1 isoforms expressed in
primary human endothelial cells in response to TSF stimulation. Each of these isoforms varies in Mr
and pI and could be the result of differential glycosylation states.
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Background
Endothelial cells line the inside of all blood vessels form-
ing an interface between circulating blood and the under-
lying tissues. As such, endothelial cells comprise, a critical
metabolic organ involved in the generation and regula-
tion of multiple physiological and pathological processes
such as coagulation, hemostasis of local vascular pressure,
inflammation, atherosclerosis, angiogenesis, and metasta-
sis [1]. In the context of the current model of tumoral dis-
semination, glycoproteins including cell adhesion
molecules are expressed on the apical endothelial mem-
brane, interacting with counter-receptors on circulating
cancer cells, facilitating the spread of the disease [2,3].
Glycoproteins are prominent constituents of biological
membranes, and are involved in various biological func-
tions, including immunological protection, enzymatic
catalysis, hormonal control, ion transport, structural sup-
port, molecular recognition, and cell adhesion. Structur-
ally, glycoproteins are comprised of a peptide backbone,
with carbohydrate chains covalently attached to asparag-
ine (N-glycan) or serine/threonine (O-glycan) residues
[4,5]. The immunoglobulin super family of cell adhesion
molecules (IgCAMs) constitutes a large group of cell sur-
face glycoproteins that are specialized for cell-cell adhe-
sion [6,7]. Recently, these molecules have been reported
to play an important role in pathological processes,
including tumor invasion and metastasis [8,9]. In particu-
lar, vascular adhesion molecule-1 (VCAM-1) is a cell sur-
face glycoprotein expressed on the apical membrane of
endothelial cells activated by cytokines [10,11]. Two iso-
forms of VCAM-1 have been reported, a full length protein
(a) and a smaller version (b) lacking exon 5. Their expres-
sion occurs in response to inflammatory mediators and is
dependent on the translocation of the transcription factor
NF-κB into the nucleus [12]. VCAM-1 interacts with its
integrin counter receptor very late antigen-4 (VLA-4), to
mediate the recruitment of leukocytes [13-15]. The adhe-
sion of tumor cells to the apical endothelial membrane
resembles their interaction with leukocytes when
endothelial cells have been activated with tumor necrosis
factor (TNF). TNF is a pro-inflammatory cytokine, princi-
pally derived from mononuclear phagocytes, that induces
transient phenotypic changes in the endothelial cells,
transforming their apical membrane from a quiescent
non-adhesive to an activated pro-adhesive surface amena-
ble for cell-cell interactions [16-18].
We have previously reported that the tumoral soluble fac-
tors (TSF's) with a very low to none TNF content can
induce a strong pro-adhesive phenotype similar to the one
induced by TNF [19-21]. Here we analyzed changes in the
content of VCAM-1 in endothelial cells under experimen-
tal treatments with TNF or TFS's that led to an increase in
tumor cell adhesion. We combined enhanced chemi-
luminescent sensitive (ECL) detection with the high
resolving power of two-dimensional polyacrylamide gel
electrophoresis (2-DE), using these techniques and the
aid of tunicamycin were able to identify undescribed iso-
forms of VCAM-1.
Results
Tumoral soluble factors (TSF's) secreted by human breast 
cancer cell lines induced adhesion of U937 myelomae cells 
to HUVECs
Using an in vitro cell adhesion assay, we found that tumor
soluble factors (TSF's) induced an activated phenotype of
HUVECs (Figure 1). The cells were stimulated for 3 h with
either TNF (10 ng/ml) or TSF's derived from breast cancer
cells lines: MCF-7 and ZR75.30 (1 μg/ml), (labeled
TSFMCF-7 and TSFZR75.30, respectively), diluted in M-
199 medium. Then, the medium containing TNF or TSF's
was removed, and the HUVECs were coincubated for 3
more h with previously radio-labeled U937 cells as was
described in methods. Compared to untreated control
cells, HUVECs treated with TNF presented a 2.6 fold
increase in cell adhesion, while those treated with
TSFZR75.30 had a 1.5 induction. The soluble factors
secreted by the other breast cancer cell line (TSFMCF-7)
did not show any adhesive effects. These results indicate
that TSFZR75.30 induced a pro-adhesive phenotype simi-
lar to that induced by TNF.
Biochemical contents of TSFZR75.30
We used a Bio-Plex system™ by BIO-RAD, CA. [16,22] to
evaluate the content of cytokines, chemokines, and
growth factors in TSFZR75.30. The results are summarized
in Table 1. TSFZR75.30 contained four cytokines (IL-6, IL-
8, G-CSF, MCP-1) that were present at levels above the
maximum measured limit. Nine cytokines (IL-2, IL-4, IL-
10, IL-5, IL-7, IL-9, IP-10, MIP-1α, RANTES) were below
the minimum measurable limit, and thirteen were present
at low levels within the detectable range, TNF was present
in this group. In comparison with the amount used (10
ng/ml), TNF was 50 times less abundant (0.22 ng/ml) in
the mixture of TSFZR75.30. Taken together, these results
suggest that TSFZR75.30 contain cytokines, chemokines,
and growth factors that are able to induce a proadhesive
phenotype in endothelial cells.
TSFZR75.30 induced the expression of VCAM-1 isoforms in 
HUVECs that disappeared when the cells were pre-treated 
with tunicamycin
VCAM-1 is a classic cell adhesion molecule, with a Mr
~80-110, that is expressed during the inflammatory
response and has also been associated with tumoral dis-
semination [23-25]. VCAM-1 is a surface molecule
reported to have two isoforms: i) the complete form (a),BMC Chemical Biology 2009, 9:7 http://www.biomedcentral.com/1472-6769/9/7
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composed of 739 amino acid residues encoded by nine
exons and containing six N-glycosylation sites that are
indispensable for protein function during molecular rec-
ognition with integrins, and ii) the small form (b), which
is composed of 647 residues and results from an alterna-
tive splicing event that removes exon 5, eliminating the
second N-glycosylation site (Figure 2A). The changes in
the cellular content of VCAM-1 were evaluated by western
blots analysis from total extracts of HUVECs treated with
either TNF or TSFZR75.30 for 6 h (Figure 2B). The content
of VCAM-1 in cells treated with TNF (10 ng/ml) and
TSFZR75.30 (1 μg/ml) was increased. The two reported
isoforms appeared as a tight doublet (VCAM-1a, Mr ~90-
95 kDa and VCAM-1b ~80-83 kDa) (lanes 3 and 5). Com-
pared to the control, VCAM-1a isoform increased 41 and
60 fold, while isoform VCAM1b increased 10 and 15 fold.
However, when we pre-treated cells for 3 h with tunicamy-
cin (1 μg/ml), an inhibitor of N-glycosylation, only the
band corresponding to isoform "a" was visible in TNF-
treated HUVECs (lane 4). In the case of treatment with the
TSFZR75.30, a new isoform was revealed, with a Mr ~77
kDa, in addition to isoform "a" (lane 6). In both cases iso-
form "b" was absent. Expression of isoform "a" and the
new isoform, labeled as "x", was increased 17 and 15 fold
respectively, to the control. It is clear that tunicamycin had
a differential effect on the glycosylation state and the con-
tent level of VCAM-1 isoforms, leading to the disappear-
ance of isoform "b" and the emergence of a undescribed
VCAM-1 isoform in cells treated with TSFZR75.30, labeled
here as isoform "x". When we performed a cell adhesion
assay similar to the one describe in Figure 1, on cell that
had been pretreated with tunicamycin (1 μg/ml) for 3 h.
The fold increase in cell adhesion induced by TSFZR75.30
fell from 3.1 ± 0.5 to 1.7 ± 0.3 in control HUVECs com-
pared to cells pretreated with tunicamycin. These results
indicate that 50% of the observed cell adhesion is depend-
ent from N-glycosylations.
2-DE analysis of total extracts of HUVECs treated with 
TNF or TSFZR75.30
In an attempt to further characterize the different VCAM-
1 isoforms visualized in Figure 2B, we prepared 2-DE gels
that were stained with a fluorescent dye (Deep purple™)
and analyzed, focusing on the regions expected to contain
these isoforms. Two dimensional electrophoresis of total
extracts from HUVECs treated with TNF presented 191
spots, 24% more than control cells (154 spots) or those
treated with TSFZR75.30 (150 spots) (Figure 3, upper
Tumoral soluble factors derived from breast cancer cell line ZR75.30 increase adhesion Figure 1
Tumoral soluble factors derived from breast cancer cell line ZR75.30 increase adhesion. The cell adhesion assay 
shows the endothelial activation, which is proportional to the adhesion of human myeloma U937 cells to HUVECs. Each bar 
represents the average of three independent experiments performed in triplicates. Statistical significance when compared to 
the control group is defined as: p < 0.05 (*) and p < 0.01 (**). The error bars indicate ± standard error of the mean.
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panels). The dotted rectangles correspond to the position
(Mr and pI) predicted for the VCAM-1 isoforms. An
amplified view of this region appears in the lower panels;
16 spots were detected with variations in intensity
between treatments. However, none of the spots repli-
cated the increase in the amounts of VCAM-1 isoforms
observed in the westerns blots from Figure 2B. It is possi-
ble that the amount of protein on the gels was not enough
to visualize the VCAM-1 isoforms.
Proteic isoforms of VCAM-1 can be observed in 2D 
westerns of HUVECs treated with TNF or TSFZR75.30
Considering that the resolution of the 2-DE gels was ade-
quate and that the western blots analysis of VCAM-1
expression yielded intense signals, we combined these
two approaches and performed 2D western blots that
revealed an unexpected variety of VCAM-1 isoforms (Fig-
ure 4). We identified the only barely visible spot in the
untreated control cells that displayed Mr/pI values close
to those reported for the full length as the VCAM-1 iso-
form "a" (Mr ~90-95 kDa/pI 4.8) (Figure 4C, left panels).
The expression of this isoform was significantly increased
when cells were treated with TNF or with TSFZR75.30.
With TNF (T) two isoforms, labeled as "b" (Mr ~80 kDa/
pI 4.6) and "c" (Mr ~83 kDa/pI 5.1-5.2), appeared below
isoform "a". With TSFZR75.30 (ZR), three spots were vis-
ible: two corresponded with spots "b" and "c" and a third
additional isoform labeled as "d" (Mr ~77 kDa/pI 5.0)
also became apparent.
Following the same strategy used in Figure 2 to reveal iso-
forms with different N-glycosylation states, we resolved
using 2D westerns blots, total extracts from HUVECs pre-
treated with tunicamycin. Figure 4C, right panels indicate
that the faint spot we previously identified as isoform "a"
in the untreated control cells disappeared after tunicamy-
cin treatment. HUVECs treated with TNF (Figure 4T, right
panels), showed a spot with the same Mr as isoform "a",
but with a shift in isoelectric point from 4.8 to 5.3-5.4,
along with a fifth isoform (labelled as "e") that appeared
as a faint spot (Mr ~77 kDa/pI 6.0). These isoforms (a and
e) were also visible in cells treated with TSFZR75.30 (Fig-
ure 4ZR right panels). The isoform "e" was the most basic
spot detected and had the same apparent Mr as isoform
"d" (Table 2). Interestingly, VCAM-1 isoform "x" seen in
Figure 2B displayed a similar Mr (75 kDa) as isoforms "d"
and "e" (77 kDa) shown in Figure 4. Thus, in addition to
the isoforms "a" and "b" previously reported in the litera-
ture, resulting from alternative splicing events, our 2D
western blots analysis revealed three new isoforms
defined by differential states of N-glycosylation.
Table 1: Elements contained (pg/ml) in TSFZR75.30 examined by Bio-Plex array.
TSFZR75.30 Maximum detected Minimum detected
IL-2 <1.3 21517 1.3
IL-4 <0.2 3854 0.2
IL-6 >33053 33053 2.0
IL-8 >24800 24800 1.5
IL-10 <1.9 30108 1.9
GM-CSF 354 10791 0.6
IFNγ 112.5 40543 2.5
TNF 22.5 70463 4.3
IL-1β 49.9 37082 2.3
IL-5 <2.4 39452 2.4
IL-7 <2.7 44339 2.7
IL-12 12.5 41843 2.5
IL-13 29.5 33114 2.0
IL-17 13 26740 1.6
G-CSF >28728 28728 1.7
MCP-1 >27978 27978 1.7
MIP-1β 15.5 37041 2.2
IL-1rα 130.5 42658 2.6
IL-9 <1.6 27064 1.6
IL-15 13 26368 1.6
Eotaxin 8.5 24294 1.5
FGF-basic 9 18355 1.1
IP-10 <4.3 69784 4.3
MIP-1α <1.1 18493 1.1
PDGF-BB 14.5 32062 1.9
RANTES <1.5 24678 1.5
VEGF 11590.5 39592 2.4BMC Chemical Biology 2009, 9:7 http://www.biomedcentral.com/1472-6769/9/7
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Expression of VCAM-1 cell content is increased when HUVECs are treated with TSFZR75.30 and decreased when cells are  pre-treated with tunicamycin Figure 2
Expression of VCAM-1 cell content is increased when HUVECs are treated with TSFZR75.30 and decreased 
when cells are pre-treated with tunicamycin. A) Exon maps of VCAM-1a: 739 amino acid, 9 exons and 6 N-glycosylation 
sites and, VCAM-1b: 647 residues, lacking exon 5 and the 2nd N-glycosylation site (hexagons). B) Western blot to detect 
VCAM-1 in twenty micrograms of total extracts from HUVECs treated for 3 hr with TNF or TSFZR75.30 (lanes 3,5) or pre-
treated with tunicamycin 3 h before TNF or TSF's (lanes 4,6). C) Histogram of the mean of three individual experiments and 
the normalized densitometric values reflecting expression of the VCAM-1 isoforms: a, b and x with respect to actin signal. p < 
0.001 (*) compared control. The error bars indicate ± standard error of the mean.
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Translocation of NF-κB to the nucleus in HUVECs treated 
with TSFZR75.30
Since VCAM-1 expression in response to TNF has been
reported to be dependent on NF-κB activation, we tested
by EMSA whether TSFZR75.30 could elicit a similar trans-
location of active NF-κB to the nucleus in HUVECs treated
with these tumoral factors. Several DNA/NF-κB com-
plexes were visible, but only complex III increased in cells
treated with TNF or TSFZR75.30 (Figure 5). While TNF
treatment led to a 4-fold increase with respect to control
cells, TSFZR75.30 led to only a 2-fold increase (lane 4),
despite the fact that this same treatment induces a strong
pro-adhesive phenotype (Figure 1). As a negative control,
we treated HUVECs with TSFMCF-7 and, as was expected,
TSFMCF-7 did not promote translocation of NF-κB. In
fact, a slight decrease in the signal was observed (lane 3).
Hence, TSFZR75.30 was able to activate and translocate
NF-κB to the nucleus.
Discussion
The interactions of tumor cells with their neighboring
endothelial cells present in their surrounding environ-
ment has emerged as an increasingly relevant factor in
tumor progression during angiogenesis, intravasation at
the primary tumor site, and adhesion and extravasation at
the site of metastasis [26-28]. The available information
indicates that the soluble factors secreted by tumor cells
can alter the phenotype of different cell types, modifying
their activity and provoking tissue destruction, tumoral
cell migration and dissemination [29]. We have previ-
ously reported that HUVECs treated with soluble factors
secreted by tumoral cells (TSF's), can adhere U937 cells
and that this response is linked to the activation of NF-κB
and the expression of cell adhesion molecules [19,30].
Since Jaffe established the methodology for the culture in
1973, HUVECs had been the principal model to the stud-
ies of physiological and pathological process involved
endothelial cells. For instance, previous studies have
investigated functional differences between HUVECs
(human umbilical vein endothelial cells) and HDMECs
(human dermal microvascular endothelial cells) with
respect to, upregulation of adhesion molecules in
response to cytokines, stimulation and expression of sur-
Informatic analyses with the program Image Master 2D Platinum™ Figure 3
Informatic analyses with the program Image Master 2D Platinum™. 50 μg of total extracts were loaded and stained 
with the Deep-Purple fluorochrome™. The 1st dimension was resolved in a linear pH-range from 3-10 and in 10% acrylamide 
for the 2nd dimension. Control (C): left panels; TNF: central panels; TSFZR75.30: right panels. Lower panels represent an ampli-
fied view of the dotted rectangle in the upper panels. Patterns are the representative images of three individual experiments 
each performed in duplicate.BMC Chemical Biology 2009, 9:7 http://www.biomedcentral.com/1472-6769/9/7
Page 7 of 13
(page number not for citation purposes)
VCAM-1 isoforms are observable in 2D western blots Figure 4
VCAM-1 isoforms are observable in 2D western blots. 50 μg of total protein from HUVECs was resolved in the 1st 
dimension in a linear pH-range from 3-10 and in 10% acrylamide in the 2nd dimension. Left panels: VCAM-1 isoforms expression 
in control and treated HUVEC's. Right panels: VCAM-1 isoforms expression observed in HUVECs with pre-treatment of tuni-
camycin. Control (C), TNF (T), TSFZR75.30 (ZR). The spot of actin was identified through a specific monoclonal antibody 
incubated at the same time as the VCAM-1 antibody. Molecular weight markers are indicated to the left of the panels and pH 
gradient markers are indicated above. The dotted grids were added to facilitate the comparison between images. Patterns are 
the representative images of two individual experiments each performed in duplicate. Numbers in parenthesis after the spot of 
the VCAM-1 isoform "a", reflect the relative amount with respect to samples without tunicamycin, each spot was normalized 
with the actin signal in the same gel, p < 0.05 (*); n = 3.
Table 2: Molecular weights and isoelectric points of VCAM-1 isoforms. 
Isoform Mr/pI NCBI Mr/pI treatments Mr/pI
tunicamycin + treatments
a 81 kDa/5.1 90-95 kDa/4.8 90-100 kDa/5.3-5.4
b 71 kDa/5.0 80 kDa/4.6 not observable
c not reported 83 kDa/5.1-5.2 not observable
d not reported 77 kDa/5.0 not observable
e not reported not observable 77 kDa/5.9-6.1
actin 42 kDa/5.3 42 kDa/5.3 42 kDa/5.3
Comparison between the values reported in the NCBI and the values observed by the treatments in the westerns of this study.BMC Chemical Biology 2009, 9:7 http://www.biomedcentral.com/1472-6769/9/7
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face antigens or mechanical properties of leukocytes roll-
ing. However, at the moment does not exist clear
functional differences. Histological studies of the expres-
sion of adhesion molecules, as such as VCAM-1 in pri-
mary vascular tumoral tissue, can serve to compare
endothelial models with the behavior of cells in vivo [31-
33].
Our current working hypothesis is that the tumor cells can
use adhesion molecules, such as VCAM-1, to interact with
and adhere to the endothelial monolayers, essentially
emulating leukocytes during the inflammatory reaction.
In this work, we compared the increase in adhesive capac-
ity of HUVEC's with the increased expression of different
VCAM-1 isoforms.
A cell adhesion assay (Figure 1) was used to compare the
pro-adhesive phenotype of HUVECs induced by TSF's.
Since different tumor cell lines present variable adhesion
to unstimulated endothelial cells, we used the promyelo-
cytic human cell line U937 as a probe of the induction of
pro-adhesive phenotype in response to the different TSF's.
This assay showed that the factors derived from the cell
line ZR75.30 (TSFZR75.30) were as effective as TNF in
activating the endothelial phenotype, using the concen-
tration of TSF's in which the percentage of adhesion (1 μg/
ml-50%), was the highest and did not have differences
statistically significatives, with respect to another concen-
trations (0.5 μg/ml-38%, 0.25 μg/ml-24%, 0.125 μg/ml-
19%, 0.0625 μg/ml-18%). TSF's by other three breast can-
cer cell lines were prepared and tested in the same cell
adhesion assay (T47D, MDA MB 435 and MDA MB 231).
Addition of 1 μg/ml of TSF's from either induced different
fold increase of adhesion: 1.3 ± 0, 1.6 ± 0.2, 2.2 ± 0.1
respectively.
TNF is recognized as the most important physiological
stimulus for the activation of signaling pathways that lead
to the translocation of NF-κB into the nucleus, for several
cell types [34-36]. In HUVECs, TNF and TSFZR75.30 both
induced the translocation of NF-κB to the nucleus,
although the TSF's only stimulated the system by about
50% in comparison with TNF (Figure 5). However, the
amount of VCAM-1 expressed was slightly higher in
TSFZR75.30 treated cells, suggesting that expression of
this adhesion molecule could result from the recruitment
of other transcription factors activated by the mixture of
elements present in the TSF's. The analysis of the mixture
of TSFZR75.30 revealed very low levels of TNF, along with
an abundance of cytokines such as IL-6 and IL-8 that
could be responsible for NF-κB activation.
The expression of adhesion molecules, such as VCAM-1,
in response to chemokines and cytokines is essential in
the acute inflammatory response and represents a clear
sign of an activated endothelial phenotype [35,37-39].
Unidimensional and bidimensional western blots analy-
sis [40,41] revealed that TSFZR75.30 was able to induce
the expression of VCAM-1a (Mr 81 kDa/pI 5.1) [NCBI
access number NP_001069] and VCAM-1b (Mr 71 kDa/pI
5.0) [NCBI access number NP_542413] in HUVECs in a
similar magnitude as TNF (Figure 2A).
In addition, the westerns showed four new isoforms: iso-
form x in uni-dimensional gels (Figure 2B) and isoforms
c, d, and e in bi-dimensional gels (Figure 4). Isoforms c, d
and e were present both, in cells treated with TNF as well
as in those treated with TSFZR75.30, although isoform d
was bearly visible in cells treated with TNF. We conclude
that TSFZR75.30 promote a stronger expression of all iso-
forms compared to the induction mediated by TNF. In an
attempt to determine if the isoforms contained N-glyco-
sylations, we interfered with the formation of dolicholpy-
rophosphate  N-acetylglucosamine, the first step in the
synthesis of N-linked glycoproteins, by using tunicamy-
EMSA assay of the NF-κB translocation to the nucleus in  HUVECs treated with TSFZR75.30 Figure 5
EMSA assay of the NF-κB translocation to the 
nucleus in HUVECs treated with TSFZR75.30. 
Nuclear extracts from HUVECs untreated and treated with 
TNF, TSFMCF-7 or TSFZR75.30, were subjected to EMSA 
using a probe for NF-κB. Roman numbers indicate NFκB/
DNA complexes. Numbers below the complexes corre-
spond to relative intensity of complex III normalized against 
the control signal, are the mean of two individual experi-
ments with independent cell cultures.
NF-kB
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cin. Under this condition, the protein portion of glycopro-
teins will be synthesized completely devoid of N-
glycosylations [42]. VCAM-1a has six N-glycosylation
sites, whereas removal of exon 5 in VCAM-1b eliminates
the second of these sites. Proteins lacking N-glycosylation
have been reported to have decreased stability in the
endoplasmic reticulum and hence, are more easily
exported and degraded in the cytoplasm by the proteas-
ome. This is a likely explanation for the decreased cellular
content of isoform "a" (40% and 70% decrease with TNF
or TSFZR75.30 respectively) and the disappearance of iso-
form "b" in the presence of tunicamycin (Figure 2B and
Figure 4).
The isoform "x" (Mr ~75-77 kDa) (Figure 2B), became vis-
ible only in the presence of tunicamycin. Considering that
one N-glycosylation modification corresponds to an
added weight of 3 kDa and that VCAM1a (90-95 kDa) has
six N-glycosylation sites, tunicamycin treatment could
lead to isoforms that are up to 18 kDa smaller. Hence, iso-
form "x" could correspond to the full length core protein
(9 exons) lacking all N-glycosylation modifications. At
this point we cannot discard that the TSFZR75.30 induce
altered glycosylation compared to that indicated by TNF.
The fact that tunicamycin pretreatment abolished 50% of
the cell adhesion induced by TSFZR75.30 indicates that
N-glycosylated proteins such as VCAM-1 play an impor-
tant rol in cell adhesion, other cell adhesion molecules
such as E-selectin and ICAM-1 are likely involved in this
process.
We assigned VCAM-1b to the spot with a Mr ~80 kDa/pI
4.6, the spot with Mr ~83 kDa/pI 5.1-5.2 we labeled as
isoform "c", which could correspond to the core protein
of isoform "b", with different pI resulting from differential
states of sialo-glycosylation at any of the five remaining N-
glycosylation sites. Alternatively, isoform "c" could also
result from the loss of exons 2 or 8, leading to a protein
with a similar Mr as "b", but with an increase in the den-
sity of charge due to the preservation of all the reported
glycosylations sites (Figure 2A).
The appearance of isoform "d", which was overexpressed
in cells treated with TSFZR75.30, could be of potential
clinical use as a biological marker for indicating the
abnormal activation of endothelial cells by tumoral fac-
tors. Isoform "d" had the lowest molecular weight, which
was suggestive of a smaller protein generated by alterna-
tive splicing or proteolytic processing. Interestingly when
we interfered the process of N-glycosylation, isoform "d"
disappeared, and a new isoform "e" (Mr ~77 kDa/pI 6.0)
appeared. The fact that these two isoforms ("d" and "e")
have the same apparent Mr suggests that they both corre-
spond to the same core protein. It is likely, that the iso-
form "x", identified in the Figure 2-B, corresponds to
isoform e, since both were visible only in the presence of
tunicamycin. According to the reported exon structure of
VCAM-1, we evaluated the possibilities for the expected
proteins when exons 2 (92 amino acids), 3 (107 amino
acids), or 8 (89 amino acids) were eliminated. The pre-
dicted proteins had the following Mr/pI values: 68928
kDa/5.13, 66997 kDa/5.14, and 69376 kDa/5.01, indicat-
ing that none of them could produce the observed "e" iso-
form, which had a Mr/pI  value of ~77 kDa/6.0. This
analysis further supports the idea that isoform "e", is
encoded by all nine exons but lacks all N-glycosylation
modifications. In addition, although we cannot discard
other types of posttranslational modifications such as
phosphorylation that could also explain the differences in
pI of the different isoforms, these modifications have not
been previously described for VCAM-1. Expression of
VCAM-1 isoforms in tumors has not been well studied. In
the past half-century, numerous studies have dealt with
the effects of TSF's on endothelial cells. These studies have
demonstrated that malignant cells produce a host of fac-
tors, most notably VEGF, that favor growth and vascular
permeability, facilitating the spread of tumors [43-45]. In
addition to cytokines and chemokines, our study also
detected significant amounts of VEGF secreted by the
breast cancer cell line ZR75.30. The complex mixture of
soluble factors secreted by these cells reflects the multifac-
torial nature of signals emitted by tumor cells that can
influence endothelial behavior [46]. The specific combi-
nation of cytokines, chemokines and growth factors,
observed in the TSF's could serve as a signature to distin-
guish between tumor cells with different metastatic or
invasive potentials in breast cancer.
Conclusion
Although it has been known for some time that altered
glycosylation patterns of cell surface proteins, in particular
increased sialylation, are associated with cancer cell adhe-
sion, mobility, and invasion, only recently the functional
significance of these changes has begun to be understood.
This study documents variants of the N-glycosylation state
of VCAM-1 that can be induced in normal endothelial
cells exposed to tumoral soluble factors derived from
human breast cancer cells that could contribute to cell-cell
adhesion and hence to malignancy [47-49].
Methods
Cell cultures
Human umbilical vein endothelial cells (HUVECs) were
isolated and cultured [50,51] by mixing cells from two or
three human umbilical cords. The protocol to obtain the
cells was approved by the ethics committee of the Gyne-
cology and Obstetrics Hospital number 4 "Luis Castelazo
Ayala", Mexican Institute of Social Security (IMSS), follow
the principles of the Helsinki Declaration for human
experimental research. Informed consent was alsoBMC Chemical Biology 2009, 9:7 http://www.biomedcentral.com/1472-6769/9/7
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obtained. The culture medium was M-199 (Gibco BRL,
Grand Island, NY), supplemented with 10% fetal bovine
serum (In vitro, D.F. Mexico), 1% glutamine (SIGMA, St
Louis, MO), 20 μg/ml endothelial mitogen (Biomedical
technologies, Stoughton, Ma), 100 μg/ml heparin
(SIGMA, St Louis, Mo), and 100 U/ml penicillin/strepto-
mycin (Gibco BRL, Grand Island, NY). Cells were grown
on plastic tissue culture plates (Costar, Cambridge, MA)
under an atmosphere of 95% humidity and 5% CO2 at
37°C. The cell culture reached confluence approximately
1 week after plating and presented a characteristic cobble-
stone appearance; cell cultures were used for all the
reported experiments within their first passage. The mye-
loma cell line (U937) and breast cancer cell lines (ZR
75.30 and MCF-7) were obtained from ATCC, cultured in
RPMI media supplemented with 10% FBS, and grown
under endotoxin-free conditions.
Production of tumoral soluble factors
Breast cancer cell lines were cultured until they reached
100% confluence. The cell layer was first washed 10 times
with phosphate-buffered saline (PBS) and DMEM (1:1 v/
v) in order to remove serum components. Then, the flasks
were incubated with 20 ml of serum free RPMI. After 48 h,
the culture medium (containing the soluble products
derived from the breast cancer cell lines) was collected
and lyophilized following centrifugation. The resulting
powder was dissolved in 1/10 of the original volume and
dialyzed using a PM-10 ultra-filtration membrane (Milli-
pore, Bedford, MA). The protein concentration was deter-
mined using the commercial Bradford reagent assay (Bio-
Rad, Hercules, CA). The resulting concentrated prepara-
tion containing the tumoral soluble factors from the
breast cancer cell line ZR75.30 (TSFZR75.30) or the breast
cancer cell line MCF-7 (TSFMCF-7), was kept at 4°C until
further use.
Adhesion assay
A suspension of U937 cells (1 × 106 cells/ml) was radio
labeled with thymidine (3H) (1 μCi/ml) (NEN, Boston,
MA) for 48 h. Aliquots of the labeled cell suspension (250
× 103 cells/250  μl) were added to previously prepared
wells containing HUVECs that had been grown and stim-
ulated for 3 h. The assay was performed in 48 well plates.
After an additional 3 h of co-incubation, all the non-
adherent U937 cells were removed by aspiration, fol-
lowed by two washes with PBS. The adherent cells were
then immediately lysed with 500 μl of 0.2 M NaOH and
the radioactivity was measured in a scintillation counter
(Beckman LS6000SC, St Louis, MO) [30].
Tunicamycin treatment
The tunicamycin concentration used was based on its N-
glycan inhibitory effects on human cell cultures. HUVECs
monolayers in Petri dishes were incubated with 1 μg/ml
tunicamycin (SIGMA, St Louis, MO) for 3 h followed by
TNF or TSFZR75.30 treatment. The cells were harvested 6
h later [52].
Western blots
Total protein concentration was determined using the
commercial Bradford reagent assay (Bio-Rad, Hercules,
CA). 20 μg of total protein was used for the detection of
VCAM-1. Samples were first boiled in sample buffer (125
mM Tris-HCl pH 6.8, 1% v/w SDS, 10%v/v glycerol, 0.1%
bromophenol blue, 2% v/v 2beta-mercaptoethanol) for 5
min and separated by 10% SDS-PAGE. Then, the gels were
transferred to PVDF membranes (Bio-Rad, Hercules, CA)
using a Trans-Blot Cell system (Bio-Rad, Hercules, CA) in
transfer buffer (25 mM Tris, 190 mM glycine, 10% meth-
anol) at 40 V overnight [53]. The following day, the mem-
branes were probed for 1 h with mouse anti-human
VCAM-1 (CD106) antibody (sc 13160 Sta. Cruz, Sta.
Cruz, CA) diluted 1:500 in TBS buffer (150 mM NaCl, 20
mM Tris, 0.1% Tween, 1% BSA, pH 7.5). After washing,
the membranes were incubated for 1 h with horseradish
peroxidase linked to antimouse immunoglobulin (Pierce
Rockford, IL). The signals were detected by enhanced
chemiluminescence using the supersignal system (Pierce
Rockford, IL) and quantified by densitometry. As a con-
trol, actin was simultaneously detected, using a mouse
anti-human actin antibody. The antibody was diluted
1:1000 and developed using the same secondary antibody
and chemiluminescence system previously described [54].
Two-dimensional gel electrophoresis
Confluent cells were either left untreated or treated for 6 h
with TNF or TSFZR75.30. Cells were rinsed twice with PBS
containing Ca++ and Mg++, and harvested in lysis buffer
containing 7 M urea, 2 M thiourea (SIGMA, St Louis,
MO), and 4% w/v CHAPS (Bio-Rad, Hercules, CA). Sam-
ples were centrifuged at 18000 g for 5 min, the superna-
tants were recovered, and the pellets were discarded. The
supernatants were then transferred to a new eppendorf
tube, and the salts were removed from the samples using
a 2-D Clean-up Kit (Amersham Biosciences, San Fran-
cisco, CA). 50 μg of total protein was mixed with DeStreak
rehydration buffer and 0.5% IPG buffer, pH 3-10 (Amer-
sham Biosciences Uppsala, Sweden) and applied to 7 cm
IPG strips, pH 3-10 (Amersham Biosciences, San Fran-
cisco, CA), which were allowed to rehydrate for 15 h at
room temperature. Separation on the first dimension was
carried out using an IPGphor II isoelectric focusing system
(Amersham Biosciences, Uppsala Sweden), as described
by Görg in 1988 [17,55]. After the first dimension, the
strips were balanced in two steps: (i) 15 min in a solution
containing 6 M urea, 50 mM Tris (pH 8.8), 30% glycerol,
2% SDS, and 70 mM DTT, and (ii) 15 min in a similar
solution contain 140 mM iodoacetamide. After mounting
the strips on 10% acrylamide gels, vertical electrophoresisBMC Chemical Biology 2009, 9:7 http://www.biomedcentral.com/1472-6769/9/7
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was carried out using the Miniprotean III Bio-Rad system
(Bio-Rad Hercules, CA). Proteins in the gels were visual-
ized with the Deep-Purple stain solution (Amersham Bio-
sciences, Bucks, UK) [1].
Deep Purple gels stain
Gels were stained according to instructions of the supplier
http://www.amershambiosciences.com/. Briefly, the gels
were first washed with distilled H2O for 30 min, and then
fixed in a solution of 7.5% acetic acid and 10% ethanol
overnight. The next day, gels were stained with 5 ml of
deep purple diluted in 200 mM Na2CO3 for 30 min and
then rinsed twice, 20 min each, with 50 ml distilled H2O
containing 7.5% acetic acid. After that, gels were briefly
washed in new last solution and imaged immediately in a
Typhoon 9410 high performance analyzer™ using the 532
nm excitation laser. Protein spots were detected and quan-
tified as fluorescent volumes; such a volume is the sum of
the intensity of all pixels within the defined spot area. The
gels with the highest number of spots were selected as ref-
erence gels and a combined warping with matching algo-
rithm was used to create an average gel [56,57].
2D Western blots
50 μg of total protein was used for the detection of VCAM-
1/actin for each of the treatments. The samples were sepa-
rated in first and second dimension following the previ-
ously described protocols and transferred to an Immuno-
blot PVDF membrane (Bio-Rad, Hercules, CA). Mem-
branes were blocked with 0.5% milk for 1 h and probed
with mouse antihuman CD106 (VCAM-1) antibody (sc
13160 Sta. Cruz, Sta. Cruz, CA) diluted 1:500 in TBS with
3% BSA overnight at 4°C, following previously described
western blots protocols.
Electrophoretic mobility shift assay (EMSA)
Nuclear protein extracts were obtained after treatments, in
which the cells were washed, scraped, and pelleted at 4°C
and then frozen in ethanol-dry ice for 1 min. The cells
were immediately resuspended in 100 μl of buffer A (10
mM HEPES, 10 mM KCl, 1.5 mM MgCl2, 1 mM DTT, pH
7.9) and incubated for 10 min at 4°C. Nuclei were micro-
centrifuged, resuspended in 30 μl of buffer B (20 mM
HEPES, 400 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA,
25% glycerol, 1 mM DTT, 0.5 mM PMSF pH 7.9), and
incubated on ice for 30 min. Following another 20 min
microcentrifuge step, the supernatant (nuclear protein
extract) was diluted with 30 μl of HDKE buffer (20 mM
HEPES, 50 mM KCl, 25% glycerol, 0.2 mM EDTA, 1 mM
DTT, 0.5 mM PMSF, pH 7.9). 10 μg of the nuclear protein
extracts were incubated with γ-ATP (32P) labeled oligonu-
cleotide containing the decameric κB site (5'AGTTGAG-
GGGACTTTCCCAGGC 3') (Santa Cruz, Sta. Cruz, CA).
The binding reactions were carried out by incubating on
ice for 40 min in reaction buffer (20 mM HEPES, 50 mM
KCl, 20% glycerol, 0.2 mM EDTA, 0.5 mM PMSF, 1 mM
DTT, 1 μg/μl BSA, 1 μg/μl poly-dI-dC) (Amersham Bio-
sciences, Uppsala Sweden). The reaction mixture was
loaded onto a 7.5% non-denaturing polyacrylamide gel,
and was resolved at 120 V for 4 h. The gel was dried and
the DNA protein complexes were visualized by exposing
the gel to a storage phosphor screen, imaged on a Storm
Phosphorimager (Molecular Dynamics, San Francisco,
CA), and analyzed with the ImageQuant software (Molec-
ular Dynamics, San Francisco, CA) [58].
Bio-Plex assay
The Bio-Plex suspension array system (Bio-Rad, Hercules,
CA) is a microsphere-based immunoassay, which utilizes
Luminex™ beads coupled to specific antibodies, as an ana-
lyte capture platform [59]. In total, 50 μl of tumoral solu-
ble factors secreted by the breast cancer cell line ZR75.30,
was used for detecting the contents of secreted factors. The
samples were added in duplicate to 96-well plates con-
taining polystyrene beads from the 27-plex assay kit, and
the beads were filter-washed twice with Bio-Plex wash
buffer using a vacuum manifold (Millipore, Bedford,
MA). Human cytokine standards were prepared in a range
of concentrations from 32,000-0.2 pg/ml, added to the
antibody-conjugated beads, and incubated in the dark on
a platform shaker for 30 min. Following incubation, the
samples and standards were removed by vacuum, and the
beads were filter-washed three times with Bio-Plex wash
buffer. Afterwards, a 1:50 dilution of biotinylated detec-
tion antibody was added to the beads, followed by incu-
bation in the dark on a platform shaker for 30 min. The
beads were washed three times and reacted with a 1:100
dilution of streptavidin-phycoerythrin (PE) for 10 min.
The beads were washed three times as described above, re-
suspended in Bio-Plex assay buffer, and analyzed on a
Bio-Plex plate reader [59,60].
Bioinformatic tools
Sequences of VCAM-1 were taken from the National
Center for Biotechnology Information (NCBI) with the
identification numbers: NP_001069 (VCAM-1a) and
NP_542413 (VCAM-1b). Determinations of Mr/pI during
the analysis of the VCAM-1 isoforms were done based on
the same sequences using the Expert Protein Analysis Sys-
tem (ExPASy) proteomics server of the Swiss Institute of
Bioinformatics (SIB).
Statistical analysis
All data sets were analyzed using two-tails Student's t test.
Abbreviations
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(2D PAGE): Two-dimensional polyacrylamide gel electro-
phoresis; (Mr): Relative mass; (pI): Isoelectric point.
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